Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis by Kim, Kyung Hoon et al.
The Korean Journal of Hepatology 2011;17:220-225
http://dx.doi.org/10.3350/kjhep.2011.17.3.220 Original Article
Peginterferon alpha and ribavirin combination therapy in 
patients with hepatitis C virus-related liver cirrhosis
Kyung Hoon Kim
1, Byoung Kuk Jang
1, Woo Jin Chung
1, Jae Seok Hwang
1, Young Oh Kweon
2, 
Won Young Tak
2, Heon Ju Lee
3, Chang Hyeong Lee
4, and Jeong Ill Suh
5
1Department of Internal Medicine, Keimyung University School of Medicine; 
2Department of Internal Medicine, 
Kyungpook National University College of Medicine; 
3Department of Internal Medicine, 
Yeungnam University College of Medicine; 
4Department of Internal Medicine, Daegu Catholic 
University College of Medicine, Daegu; 
5Department of Internal Medicine, 
Dongguk University College of Medicine, Gyeongju, Korea
Background/Aims: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a 
higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study 
evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related 
cirrhosis. Methods: Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a 
(n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were 
analyzed retrospectively. Results: Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38 
(44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and 
non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV 
genotype 1 (P=0.003) and high baseline viral load (>8.0×10
5 IU/mL, P=0.012) were the independent predictive factors for SVR 
failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%), 
and other reasons (22.2%). Conclusions: Peginterferon and ribavirin combination therapy was relatively effective and feasible 
for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load. (Korean J 
Hepatol 2011;17:220-225)
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INTRODUCTION
Hepatitis C virus (HCV) infection may affect 2.5-3.0% of the 
world’s population.
1 Among Koreans older than 40 years, 1.3% 
are positive for HCV antibodies.
2 Liver cirrhosis may develop 
in 20% of those infected and 1-4% of the patients with 
cirrhosis may develop hepatocellular carcinoma (HCC) annually.
3 
Combination therapy with pegylated-interferon (peginterferon) 
and ribavirin reduces the rate of progression of liver fibrosis in 
patients with chronic hepatitis C.
4 Interferon treatment for 
patients with HCV-related liver cirrhosis inhibits the development 
of HCC and it improves survival.
5 These results indicate that 
cirrhotic patients with chronic hepatitis C as well as patients with 
chronic hepatitis C should be treated to prevent progression of 
cirrhosis and the development of HCC. Combination therapy 
with peginterferon and ribavirin is the optimal treatment for 
patients with chronic HCV infection.
6 The sustained virologic 
response (SVR) rate for patients with HCV genotype 1 and HCV 
genotype 2 or 3, who received peginterferon alpha and ribavirin 
combination therapy was reported to be 42-46% and 76-80%, 
respectively.
7,8 It was shown that the SVR rate for patients with 
uncomplicated, biopsy-proven HCV cirrhosis was 33-48%.
7,9 
However, there is little data on patients who have been diagnosed 
as having HCV cirrhosis by radiological evaluation and/or who Kyung Hoon Kim, et al. Peginterferon and ribavirin therapy in HCV cirrhosis patients  221
have thrombocytopenia or esophageal and gastric varices seen 
on upper endoscopy. 
The aim of this study was to evaluate the SVR rate, the 
completion rate of treatment, the causes of discontinuation of 
treatment and the adverse events in patients with clinically 
diagnosed liver cirrhosis and who received peginterferon and 
ribavirin combination therapy. 
PATIENTS AND METHODS
Patients
We investigated the patients with HCV-related cirrhosis who 
Visited 5 tertiary care academic medical centers in Daegu and 
North Gyeongsang Province from August 2005 to February 
2008. The inclusion criteria were (1) positivity for HCV 
antibodies and RNA, (2) Child-Pugh class A, (3) platelet count 
>75,000/mm
3, (4) AFP level < 50 ng/mL and (5) liver cirrhosis 
diagnosed by radiological evaluation or by detected esophageal 
and gastric varices on upper gastrointestinal endoscopy. The 
exclusion criteria were (1) history of decompensated liver cirrhosis 
(ascites, variceal bleeding, jaundice and hepatic encepha-
lopathy), (2) hepatocelluar carcinoma, (3) HBs Ag positivity and 
(4) severe depression and severe cardiopulmonary disease not 
controlled by therapy. Evidence of portal hypertension was 
defined as presence of esophageal varices and/or by a baseline 
platelet count <100,000/ mm
3 and splenomegaly on ultrasono-
graphy.
Study design
The quantitative HCV-RNA was assessed using Amplicor 
HCV amplification kit (version 2.0, Roche Molecular diagnostics, 
IN, USA) and the qualitative HCV-RNA was tested by either 
Amplicor HCV monitor Kit (version 2.0, Roche Molecular 
diagnostics, IN, USA) or Abbott real-time kit (Abbott Molecular 
Inc., Abbott Park, IL, USA). HCV genotyping was performed by 
VERSANT
Ⓡ HCV genotype assay (LiPA, Bayer, NY, USA). The 
patient with HCV genotype 1 received either peginterferon 
alpha-2a (40 kd) (Pegasys, Hoffmann-La Roche, Nutley, NJ, 
USA) 180 μg SQ once weekly regardless of their weight or 
peginterferon alpha-2b (12 kd) (Peg-Intron, Schering- Plough 
Corporation, Kenilworth, NJ, USA) 1.5 μg/kg SQ once weekly 
plus ribavirin 1,000 mg PO daily for the patients weighting <75 
kg or 1,200 mg PO daily for the patients weighting ≥75 kg (in 2 
divided doses) for 48 weeks. The patients with HCV genotype 
non-1 received either peginterferon alpha-2a 180 μg SQ once 
weekly regardless of weight or peginterferon alfa-2b 1.5 μg/kg 
SQ once weekly plus ribavirin 800 mg PO daily regardless 
of weight (in 2 divided doses) for 24 weeks. The dose of 
peginterferon was reduced if the absolute neutrophil count 
(ANC) declined to 750/mm
3 or the platelet count declined to 
50,000/mm
3. It was stopped if the ANC declined to 500/mm
3 or 
the platelet count declined to 30,000/mm
3. The ribavirin was 
lowered if the hemoglobin declined to 10.0 g/dL and it was 
stopped if the hemoglobin declined to 8.0 g/dL.
Assessment of efficacy and the adverse events
Early viral response (EVR) was defined as at least a 2 log 
reduction in the HCV RNA level at 12 weeks of therapy. End 
of treatment response (ETR) was defined as the absence of 
detectable HCV-RNA at the end of therapy. Sustained 
virological response (SVR) was defined as the absence of serum 
HCV-RNA at the end of therapy and 24 weeks later. Adverse 
events were assessed by clinical evaluation and laboratory tests 
at regular intervals.
Statistical analysis
The data was analyzed by SPSS 13.0 for Window software 
(SPSS Inc., Chicago, IL, USA). Continuous variables were 
expressed as means±standard deviation (SD) and the differences 
between the continuous data were analyzed by t-tests. The 
factors influencing the SVR and the association between the 
HCV genotype and the ETR or SVR were analyzed by Fisher’s 
exact test and the logistic regression model. A significance level 
of P=0.05 was used.
RESULTS
Patient characteristics
A total of 86 patients were enrolled in this study. Of them, 68 
(79.1%) patients completed the treatment (mean age: 56.4±9.6, 
males: 61.7%, HCV genotype 1: 46.7%) (Fig. 1). A total of 18 
patients stopped treatment. The causes of discontinuation of 
treatment for the HCV genotype 1 patients were adverse events 
(4 patients, 30.7%), loss to follow-up (6 patients 46.2%), and 
other problems like lack of money (3 patients, 23.1%). For the 
HCV genotype non-1 patients, 5 patients stopped the treatment 
due to loss to follow-up (3 patients, 60%), adverse events 
(1 patient, 20%) and other problems (1 patient, 20%) (Table 1). 222  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Figure 1. Patient flow diagram. 
EVR, early virologic response; SVR, sustained virological response.
Table 1. Baseline characteristics of patients according to HCV genotype
Genotype 1 (n=48) Genotype non-1 (n=38) P-value
Gender
  Male 31 (64.6%) 24 (63.2%) 0.891
*
  Female 17 (35.4%) 14 (36.8%)
Age (years, mean±SD) 54.5±11.3 56.9±8.7 0.281
†
Age >65 years 10 (20.8%) 6 (15.8%) 0.551
*
ALT (IU/L, mean±SD) 75.0±52.9 66.5±69.2 0.522
†
AST (IU/L, mean±SD) 81.7±43.1 89.5±57.2 0.471
†
Total bilirubin (mg/dL, mean±SD) 1.1±0.5 0.9±0.4 0.03
†
ALP (IU/L, mean±SD) 127.5±63.4 146.3±109.0 0.349
†
Albumin (g/dL, mean±SD) 4.1±0.5 4.1±0.5 0.656
†
Platelets (×10
3/mm
3, mean±SD) 131.1±52.0 140.4±59.3 0.442
†
HCV RNA, 
  mean±SD (×10
5 IU/mL) 23.2±36.9 11.1±14.1 0.041
†
  >8.0×10
5 IU/mL 26 (54.2%) 16 (42.1%) 0.266
*
Portal hypertension 22 (45.8%) 14 (36.8%) 0.627
*
Peginterferon  α-2a/α-2b 27/21 (56.3/43.8%) 24/14 (63.2%/36.8%) 0.517
*
Peginterferon dose reduction 9 (20.0%) 9 (25.0%) 0.789
*
Ribavirin dose reduction 12 (26.7%) 9 (25.7%) 1.000
*
* Pearson Chi-Square, 
†Student  t-test. 
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosthatase; HCV, hepatitis 
C virus.
There was no patient who stopped  the treatment due to hepatic 
dysfunction or development of complications related to liver 
cirrhosis. The baseline characteristics in each genotype groups 
were similar for age, ALT and other characteristics except the 
baseline serum HCV RNA level and total bilirubin. The baseline 
serum HCV RNA level and total bilirubin were significantly 
higher in the genotype 1 patients than those in the genotype non-1 
patients (Table 1). Thirty-five patients (51.5%) were diagnosed 
as liver cirrhosis by radiological evaluation only, and 33 
patients (48.5%) were diagnosed by radiologic evaluation, and 
by presence of esophageal and/or gastric varices  on upper 
gastrointestinal endoscopy. Fifty one patients received peginter-
feron alpha-2a and 35 patients received peginterferon alpha-2b. 
The mean duration of follow-up was 23.0±11.9 months from the 
initial treatment.
Virological response
On the intention-to-treat analysis, the overall ETR and SVR 
rates were 55.8% (48/86) and 34.9% (30/86), respectively. The 
ETR was achieved in 21/48 (43.8%) and 27/38 (71.1%) of the 
patients with HCV genotype 1 infection and HCV genotype 
non-1 infection, respectively (P=0.011). The SVR rates were 
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Table 2. Factors influencing SVR by univariate analysis
Patients with SVR (n=30) Patients without SVR (n=56) P-value
Gender 0.930
*
  Male 19 (63.3%) 36 (64.3%)
  Female 11 (36.7%) 20 (35.7%)
Age >65 years 3 (10.0%) 13 (23.2%) 0.158
†
ALT >100 IU/L 5 (16.7%) 13 (23.2%) 0.584
†
HCV genotype 1 10 (33.3%) 38 (67.9%) 0.002
*
HCV RNA >8.0×10
5  IU/mL 9 (30.0%) 33 (58.9%) 0.011
*
Portal hypertension 9 (30.0%) 27 (48.2%) 0.103
*
Peginterferon  α-2a/α-2b 20/10 (66.7%/33.3%) 31/25 (55.4%/44.6%) 0.309
*
* Pearson Chi-Square, 
†Fisher’s Exact Test. 
SVR, sustained virological response; ALT, alanine aminotransferase; HCV, hepatitis C virus.
Figure 2. End of treatment response (ETR) and SVR rates 
according to HCV genotypes. ETR and SVR rates were 
significantly higher in patients with genotype non-1 than in those 
with genotype 1 (71.1% vs. 43.8%, P=0.011; and 52.6% vs. 
20.8%,  P=0.002, respectively).
Table 3. Factors influencing SVR failure by multivariate analysis
Odds ratio 95% confidence interval P-value
HCV genotype 1 4.464 1.688-13.445 0.003
HCV RNA >8.0×10
5 IU/mL 3.913 1.349-11.346 0.012
* Logistic regression analysis. 
SVR, sustained virological response; HCV, hepatitis C virus.
genotype non-1 infection patients (20/38) (20.8% vs. 52.6%, 
p=0.002, respectively) (Fig. 2). In per-protocol analysis, Of the 
68 patients who completed treatment, the overall SVR rate was 
44.1% (30/68). The ETR and SVR rates of the HCV genotype 1 
and genotype non-1 patients were 60.0% (21/35) and 28.6% 
(10/35), and 81.8 (27/33) and 60.6% (20/33), respectively.
Factors associated with SVR
On the univariated analysis, HCV genotype 1 and high 
baseline viral load (HCV RNA >8.0×10
5 IU/mL) were associated 
with low SVR rate (P=0.008, P=0.010) (Table 2). However, old 
age (>65 years), gender, the baseline alanine aminotransferase 
(ALT) level, portal hypertension, the types of peginterferon and 
dose reduction of peginterferon and ribavirin were not associated 
with the SVR rate. On the multivariated analysis, HCV genotype 
1 (P=0.003; odds ratio, 4.464) and high baseline viral load 
(P=0.012; odds ratio, 3.913) were also independent factors for 
low SVR rate (Table 3).
Tolerability and adverse events
Five patients stopped the treatment due to adverse events. The 
types of adverse events were thrombocytopenia (2 patients), 
depression (1 patient), anxiety disorder (1 patient) and cerebral 
vascular hemorrhage (1 patient). The other profiles of adverse 
events were “flu-like” symptoms, neutropenia, anemia, thrombocy-
topenia, depression, anorexia, fatigue, myalgia, headache, 
insomnia, nausea, weight loss, itching, alopecia and rash 
(Table 4). The peginterferon dose had to be reduced in 18 
patients (20.9%) and the ribavirin dose had to be reduced in 21 224  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
Table 4. Frequencies of adverse events (N=86)
Adverse events Frequency (%)
Flu-like symptoms 16 (18.6%)
Myalgia 12 (14.0%)
Thrombocytopenia 12 (14.0%)
Itching 9 (10.5%)
Alopecia 8 (9.3%)
Fatigue 8 (9.3%)
Anemia 7 (8.1%)
Anorexia 6 (7.0%)
Insomnia 5 (5.8%)
Neutropenia 4 (4.7%)
Weight loss 3 (3.5%)
Depression 3 (3.5%)
Headache 2 (2.3%)
Rash 2 (2.3%)
Nausea 1 (1.2%)
Cerebral hemorrhage 1 (1.2%)
patients (24.4%). The rate of peginterferon dose reduction was 
not significantly different between peginterferon alpha 2a 
(14/51) and alpha 2b (4/35) (27.5% vs. 11.4%, P=0.105). The 
presence of portal hypertension was not related to dose reduction 
rates of peginterferon (27.8%, 10/36) and ribavirin (25.0%, 9/36) 
(P=0.282, P=1.000).
DISCUSSION
The SVR rate for patients with compensated, biopsy-proven 
HCV cirrhosis is 34-53%, which was lower than that of the 
chronic hepatitis patients without cirrhosis.
7-8,12 The SVR rate for 
HCV cirrhotic patients with portal hypertension is 21.6%.
13 In 
our study, the overall SVR rate of patients who were clinically 
diagnosed as cirrhosis was 34.9%. This was lower than that of the 
patients who were diagnosed as cirrhosis through liver biopsy in 
other studies,
14 but slightly higher than those of studies on 
patients with portal hypertension. Liver histological examination 
based on percutaneous needle biopsy is considered as a gold 
standard method for diagnosis of liver cirrhosis. However, liver 
biopsy cannot be performed routinely at clinical practice because 
of complication risk and patients' discomforts. Therefore, in 
actual clinical setting, radiologic examinations such as abdominal 
ultrasonography or computed tomography are regularly performed 
for viral hepatitis patients. These radiologic examinations are 
difficult to clearly distinguish between chronic hepatitis and 
cirrhosis. However, there are many reports saying that 
specificity is very high although sensitivity is relatively low, 
when there are such manifestations as irregular liver surface, 
nodular liver parenchyma, atrophy of right hepatic lobe, 
hypertrophy of caudate lobe and left hepatic lobe, and 
splenomegaly.
10,11 Therefore, if the abdomen US or CT finds the 
typical manifestations of cirrhosis, it means that the patient is 
highly likely to have liver cirrhosis. In clinical settings, most 
patients who are diagnosed as liver cirrhosis by radiologic 
imaging or endoscopic finding are likely to be treated with 
peginterferon and ribavirin without liver biopsy.
In cirrhotic patients, the SVR rate of the genotype non-1 group 
was similar at around 52.6%. The SVRs of genotype 1 group was 
reported to be very low at 13-14%,
14,15 however, the SVR was 
relatively high at 20.8% in this study. This was consistent with 
the results of relatively high SVRs in Korean patients compared 
to those in Western countries in studies with patients who did not 
have liver cirrhosis, but the accurate reason is unknown.
16,17 
Furthermore, in this study, even the SVR rate of patients with 
portal hypertension who showed splenic enlargement in imaging 
study, thrombocytopenia, or esophageal or gastric varices in 
upper gastrointestinal endoscopy was 30.0% (9/30), which was 
better than the results of other studies. There was no significant 
difference in SVR, compared to patients who did not have portal 
hypertension. However, the clinical judgment on portal hypertension 
may be subjective and the number of patients is small in our 
study. Therefore, accurate diagnosis methods such as measurement 
of hepatic venous pressure gradient for the assessment of portal 
hypertension, and studies with a larger number of patients may 
be needed.
It is generally well-known that chronic hepatitis C patients 
without cirrhosis show low SVR if they have HCV genotype 1 
and have high viral load before the treatment. It has also been 
reported that these factors are associated with SVR in patients 
with compensated liver cirrhosis.
8,18,19 The present study also 
found that only these two factors were associated with SVR, 
which is consistent with the results of other studies.
In our study, there were 5 patients (5.8%, 5/86) who discontinued 
treatment due to adverse reactions of peginterferon and ribavirin 
combination therapy. This was similar to about 6.0-10.3% 
reported in domestic studies on chronic hepatitis C patients,
16,17 
but lower than 16.0-32.3% reported in studies on patients who 
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hypertension.
13,14 However, simple comparison is not warranted 
because this was a retrospective study, and there is the possibility 
that some of the 9 patients (10.5%) who were not followed up 
without particular reason may voluntarily discontinued the 
treatment due to other side effects than hematological adverse 
reactions. Nevertheless, as treatment stopped in less than 20% of 
patients when these patients were included, the number of cases 
who stopped treatment due to adverse reactions of peginterferon 
and ribavirin combination therapy in patients with cirrhosis was 
similar to that of chronic hepatitis C patients. Of 86 patients, the 
patients who reduced peginterferon and ribavirin due to 
hematological adverse reactions were 20.9% (18/86) and 24.4% 
(21/86), respectively. These rates of dose reduction were not 
significantly greater in patients with portal hypertension, although 
hematologic adverse reaction expected to be more frequent.
As the limitation of retrospective study, we could not follow 
up every patients who had started the treatment to the completion 
of treatment, and the medical records were not standardized and 
consistent by organization. Therefore, so it is difficult to arrive at 
final conclusions. However, even schematically, this study 
confirmed the expected results and possible adverse reactions of 
the peginterferon and ribavirin combination therapy in chronic 
hepatitis C patients who were clinically diagnosed with cirrhosis. 
In conclusion, the overall SVR can be achieved in one-third of 
clinically diagnosed cirrhosis patients with HCV infection. 
Especially for patients with genotype non-1 infection, the SVR 
rate was high. Therefore, planning treatment on the basis of viral 
genotype and baseline viral load are needed to select patients 
who are more likely to achieve SVR.
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